Stafinski Tania, Menon Devidas, Nardelli Alex, Bakal Jeff, Ezekowitz Justin, Tymchak Wayne, Welsh Robert, Gyenes Gabor, Armstrong Paul W
Health Technology & Policy Unit, School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
Am Heart J. 2015 Jan;169(1):122-31.e22. doi: 10.1016/j.ahj.2014.10.002. Epub 2014 Oct 13.
Traditionally, clinical outcomes comprising composite end points in cardiovascular trials are assigned equal weights in statistical analyses. However, the importance of weighting outcomes according to their relative severity is now recognized. This study aimed to elicit patients' perceptions of the importance of cardiovascular outcomes and treatment complications and compare them with those of clinicians.
Interviewer-administered surveys, including rating, ranking, point-allocation and trade-off exercises, were conducted in 52 adults with confirmed coronary disease or previous myocardial infarction. Patients viewed "death" as the most severe cardiovascular outcome, followed by cardiogenic shock, congestive heart failure (CHF), and repeat myocardial infarction (re-MI), the same pattern observed in clinician responses in a previous study. Most patients were willing to accept a 3-fold increase in risk of systemic bleed (SB) or nonfatal intracranial hemorrhage (ICH) for a 20% reduction in risk of cardiogenic shock or 60% reduction in risk of CHF, but only a 2-fold increase in the risk of SB or ICH for a 20% reduction in risk of CHF or 60% reduction in risk of re-MI and no increase in risk of SB or ICH for a 20% reduction in risk of re-MI. Similar patterns were seen in a previous study of trade-offs in clinicians.
Although patients' preferences appear to be comparable with those of clinicians, patients may be less willing than clinicians to tolerate potential treatment complications. The methods used in this study offer a feasible approach to incorporating patient preferences into cardiovascular trials and warrant further investigation in broader patient populations.
传统上,心血管试验中包含复合终点的临床结局在统计分析中被赋予同等权重。然而,现在人们认识到应根据结局的相对严重程度进行加权。本研究旨在了解患者对心血管结局和治疗并发症重要性的看法,并将其与临床医生的看法进行比较。
对52名确诊为冠心病或既往有心肌梗死的成年人进行了由访谈者实施的调查,包括评分、排序、分值分配和权衡练习。患者将“死亡”视为最严重的心血管结局,其次是心源性休克、充血性心力衰竭(CHF)和再次心肌梗死(re-MI),这与先前一项研究中临床医生的回答模式相同。大多数患者愿意接受全身出血(SB)或非致命性颅内出血(ICH)风险增加3倍,以换取心源性休克风险降低20%或CHF风险降低60%,但仅愿意接受SB或ICH风险增加2倍,以换取CHF风险降低20%或re-MI风险降低60%,而对于re-MI风险降低20%则不愿意接受SB或ICH风险增加。在先前一项关于临床医生权衡的研究中也观察到了类似模式。
尽管患者的偏好似乎与临床医生的偏好相当,但患者可能比临床医生更不愿意容忍潜在的治疗并发症。本研究中使用的方法为将患者偏好纳入心血管试验提供了一种可行的方法,值得在更广泛的患者群体中进一步研究。